Menopause

Summary

Menopause is a natural, age-related decline in ovarian function that marks the end of a woman’s reproductive capacity, defined retrospectively after 12 consecutive months of amenorrhea without other causes. It progresses through four phases: premenopause, perimenopause, menopause, and postmenopause — each characterized by distinct hormonal and clinical changes. The median age of menopause globally and in Jordan is approximately 51 years.

Declining estrogen and progesterone levels lead to symptoms including vasomotor disturbances (e.g., hot flashes), genitourinary syndrome of menopause (GSM), mood and cognitive changes, and increased risk of osteoporosis and cardiovascular disease.  Diagnosis is primarily clinical, with selective laboratory evaluation. Management includes lifestyle modifications, hormone replacement therapy (HRT) for moderate to severe symptoms, nonhormonal alternatives, and routine screening for long-term complications.

Definition

Menopause is defined as the permanent cessation of menses following loss of ovarian follicular activity, confirmed retrospectively after 12 months of spontaneous amenorrhea without other causes.
It results from the age-related decline in ovarian follicular activity, leading to decreased estrogen and progesterone production, and elevated gonadotropins (FSH and LH).

Note:

• Median age of natural menopause: ~51 years (range 45–56 years)

• Smokers and malnourished women tend to experience earlier onset.

• Vaginal pH rises after menopause (>5), predisposing to infections due to decreased lactobacilli and loss of vaginal glycogen. ( question idea)

Phases of the Female Reproductive Lifespan

Pathophysiology

• Menopause results from progressive depletion of ovarian follicles, leading to:

• ↓ Estrogen and progesterone

• Loss of negative feedback → ↑ GnRH → ↑ FSH and LH (hypergonadotropic hypogonadism)

• Resultant anovulatory cycles, eventual ovarian failure

• Iatrogenic causes (e.g., oophorectomy, chemotherapy) result in induced menopause with abrupt hormonal decline and more severe symptoms.

Clinical Features

Menstrual Changes

• Early perimenopause: shorter, irregular cycles

• Late perimenopause: cycles ≥60 days apart

• Final stage: complete amenorrhea

• May be accompanied by heavy menstrual bleeding

Vasomotor Symptoms (VMS)

• Hot flashes, night sweats, heat intolerance, sleep disruption.

• Affect ~75% of women

• Average duration:7–9 years (may persist >10 years in some)

• More severe in surgically induced or premature menopause

Genitourinary Syndrome of Menopause (GSM)

• Vulvovaginal atrophy: dryness, dyspareunia, irritation, postcoital bleeding

• Urinary tract changes: dysuria, urgency, incontinence, recurrent infections

• Vaginal pH increases from 3.5–4.5 to >5

• Progressive and chronic unless treated with local estrogen therapy

Neuropsychiatric and Cognitive Symptoms

• Sleep disturbances, mood lability, anxiety, depression

• Cognitive complaints (“brain fog,” decreased memory and focus)

• Fatigue and vertigo may occur

Sexual and Physical Changes

• Decreased libido and arousal

• Weight gain and central adiposity

• Skin thinning, hair loss, hirsutism (relative androgen excess)

Long-Term Health Risks

• Osteoporosis (accelerated bone resorption within first 5–7 years postmenopause)

• Cardiovascular disease (loss of estrogen’s cardioprotective effect → ↑ LDL, ↓ HDL)

• Urogenital prolapse and urinary incontinence

Subtypes and Special Cases

Diagnosis

Clinical

• Diagnosis is clinical unless atypical features are present.

• Women ≥40 years with typical symptoms and menstrual changes.

Laboratory (as indicated)

• ↑ FSH (>30 IU/L) and ↓ estradiol: support diagnosis (but fluctuate during perimenopause).

• Other tests to exclude differential diagnoses:

  • TSH, prolactin, β-hCG

  • Androgens (if virilization, signs of hyperandrogenism present)

• Pelvic ultrasound or endometrial biopsy if abnormal uterine bleeding or postmenopausal bleeding

Complications

• Osteoporosis: due to hypoestrogenism and impaired bone remodeling

• Cardiovascular disease: due to loss of estrogen’s vascular protective effects, associated with increased LDL, triglycerides, and hypertension

• GSM: progressive vaginal and urinary symptoms.

• Postmenopausal bleeding: must always be investigated for endometrial carcinoma

• Cognitive decline and increased risk of metabolic syndrome

Management

Lifestyle Measures

• Balanced diet with adequate calcium (1,200 mg/day) and vitamin D (800–1,000 IU/day)

• Regular weight-bearing exercise (≥30 min/day)

• Smoking and alcohol cessation

• Avoid triggers for hot flashes (spicy foods, caffeine)

• Stress reduction, yoga, mindfulness, sleep hygiene
  
  

Pharmacologic Therapy

Hormone Replacement Therapy (HRT)

• Indications:

• Moderate to severe VMS or GSM

• Premature or early menopause

• Prevention of osteoporosis (select cases)
  
  

• Forms:

• Estrogen + progestin (for women with uterus)

• Estrogen-only (for hysterectomized women)

• Routes: oral, transdermal, or transvaginal
  
  

• Contraindications:

• Estrogen-dependent malignancy (e.g., breast, endometrial cancer)

• Undiagnosed vaginal bleeding

• Active or history of thromboembolism, stroke, or CAD

• Severe Liver disease
  
  

• Adverse Effects:

• Breast tenderness, bloating, mood changes

• Long-term risks: ↑ DVT, stroke, breast cancer (with combined therapy >5 years)
  
  

Vaginal Estrogen Therapy

• Indicated for isolated GSM without systemic symptoms

• Forms: creams, tablets, rings, vaginal DHEA

• Minimal systemic absorption; safe for long-term use

• Avoid in estrogen-dependent cancer unless approved by oncologist

Nonhormonal Options

Screening and Preventive Care

• Bone density testing (DEXA) in women ≥65 or younger with risk factors

• Cardiovascular risk assessment: BP, lipids, glucose

• Cancer screenings as age-appropriate, breast (mammography), cervical (Pap/HPV), colon.

• Monitor psychological health and refer for counseling if needed